ClinicalTrials.gg
CompletedNCT05610150Updated Feb 1, 2024

Pharyngeal Airway Dimensions With Twinblock Versus Myobrace Appliances in Developing Skeletal Class II Patients

An interventional study of Myobrace Functional Appliance and Twin Block in Malocclusion, Angle Class II, Division 1, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 9 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Apr 2022, registered Nov 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
9 Years to 12 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the pharyngeal airway changes after treatment with Myobrace and after treatment with Twinblock in developing skeletal Class II patients.

The main question it aims to answer is: Is the efficacy of the twin-block Vs Myobrace appliances in the improvement of pharyngeal airway dimensions in adolescents having skeletal Class II malocclusion with retrognathic mandible utilizing sagittal pharyngeal airway area measurements.

02

Conditions studied

  • Malocclusion, Angle Class II, Division 1

Keywords

  • Airway
  • Myobrace
  • Twinblock
03

In context

Malocclusion, Angle Class II

124 studies on the registry are indexed under Malocclusion, Angle Class II; 19 are open to participants now.

This study's enrollment of 26 is below the median of 34 across 115 interventional studies indexed under Malocclusion, Angle Class II.

Browse Malocclusion, Angle Class II studies →

Lead sponsor

Alexandria University is the lead sponsor of 604 studies on the registry; 140 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy children
  • 9-12 Years
  • Skeletal Class II with mandibular defeciency and normal maxillary growth depending on clinical diagnosis and confirmed with lateral cephalometric x-reay readings ( ANB angle >4 and SNA angle \<78)

Exclusion criteria

Exclusion Criteria:

  • Previous Orthodontic treatment
  • Previous extractions
  • mandibular shifts
  • Severe Crowding
  • Anterior open bite
  • Any perioral habits
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    Myobrace functional Appliance

    Thirteen patients with developing skeletal Class II malocclusion will be treated with Myobrace functional appliance for six months.

    Device: Myobrace Functional Appliance

  • Active comparator
    Twin Block Functional appliance

    Thirteen patients with developing skeletal Class II malocclusion will be treated with Twinblock functional appliance for six months.

    Device: Twin Block

Interventions

  • DeviceMyobrace Functional Appliance

    An Appliance for treating growing Class II patients with mandibular deficiency

  • DeviceTwin Block

    An Appliance for treating growing Class II patients with mandibular deficiency

06

What researchers measure

Primary outcomes

  1. SNA

    Angle formed between points Sella, Nasion and A point and describes anteroposterior position of the maxilla relative to the anterior cranial base.

    Time frame: Six months

  2. SNB

    Angle formed between points Sella, Nasion and B point and describes anteroposterior position of the mandible relative to the anterior cranial base.

    Time frame: Six months

  3. ANB

    Angle formed between points A, Nasion and B point indicating the skeletal relationship between the maxilla and the mandible.

    Time frame: Six months

  4. Witts appraisal

    The linear distance between the perpendicular projections of points A and B over the functional occlusal plane.

    Time frame: Six months

  5. FMA

    Angle formed between mandibular plane and Frankfort horizontal plane.

    Time frame: Six months

  6. Pharyngeal air way area measurement

    The upper border of Naso Pharyngeal air way area will be delineated by a line extending from the harmonium (H) to the posterior nasal spine. The lower extent of the NPAA will be traced by marking a line at the tip of the soft palate parallel to the Frankfort horizontal (FH) plane extending to the posterior wall of the pharynx. The OPAA and LPAA are differentiated by a line drawn at the level of the tip of epiglottis parallel to the FH plane to the posterior wall of the pharynx. The lower border of the LPAA is defined as a line drawn parallel to FH plane and passing through the anteroinferior most point (C5AI) of the fifth cervical vertebra. Area will be measured.

    Time frame: Six months

07

Study locations

1 site
  • Ahmed Median
    Alexandria, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Apr 2023, 12 months.

Of 86 non-industry interventional studies with no phase under Malocclusion, Angle Class II, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's 12 months is below that.

Counting every sponsor, half of 86 studies reached it within 15 months; a quarter within 11 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2022
First posted
Nov 9, 2022
StartActual
Apr 1, 2022
Primary completionActual
Apr 15, 2023
CompletionActual
Apr 30, 2023
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05610150
Responsible party
Sponsor
First posted
Nov 9, 2022
Start date
Apr 1, 2022
Primary completion
Apr 15, 2023
Completion
Apr 30, 2023
Last update
Feb 1, 2024

Study contacts

Ahmed Median, PhD
study director · Alexandria University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion